InfuSystem (INFU) Q2 EPS Jumps 300%
InfuSystem (NYSEMKT:INFU), a healthcare services and medical equipment company specializing in infusion therapy, released its second quarter 2025 earnings on August 5, 2025. The key news: profitability was well ahead of expectations, with GAAP EPS of $0.12 exceeding the analysts' estimate of $0.036 by 233.3%, with diluted earnings per share (EPS) of $0.12 (GAAP), compared to analyst forecasts of $0.036. At the same time, GAAP revenue reached $36.0 million, just under the $36.11 million consensus expectation and up from $33.7 million (GAAP) in the prior year. The period saw strong expense control and margin improvement, most notably in the Device Solutions segment, but also a tempered outlook for full-year 2025 revenue growth, with guidance revised to 6% to 8% due to slower progress in new product lines. Overall, the period reflected operational strength but revealed softer momentum in top-line expansion, as GAAP net revenues grew 6.8%.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
InfuSystem provides infusion pumps and related services for patient care. Its business centers on supporting hospitals, clinics, and patients needing continuous or ambulatory infusion therapy. The company generates most of its revenue from the oncology market, where continuous drug delivery is increasingly used in outpatient cancer treatments.
Source Fool.com
